Literature DB >> 9679225

A semiparametric method for describing noisy population pharmacokinetic data.

K Park1, D Verotta, T F Blaschke, L B Sheiner.   

Abstract

We propose a semiparametric method to estimate model-independent pharmacokinetic (PK) measures such as area under concentration-time, peak concentration and time to peak concentration (Tpeak), for noisy population PK data from a sparsely sampled prospectively designed trial. The method is developed within the mixed-effect model framework, for the single-dose and steady-state case. We describe individual concentration vs. time using a longitudinal spline, consisting of a template spline, common to all individuals, and an individual-specific distortion spline accounting for individual differences. We impose a number of constraints on the longitudinal spline, including (i) it has a decreasing tail, (ii) its typical Tpeak is near the modal Tpeak observed in the population data, and (iii) its value is zero at time zero (single dose), or the same nonzero value at the beginning and end of a dosing interval (steady state). We test our method using simulated data and compare its performance to that of a parametric and a nonparametric method. An actual data example is also shown. The performance of the method is as good or better than that of a standard nonparametric method, and when the analysis model is misspecified, the method is superior to a standard parametric one. Since it is often not apparent that an analysis model is correct, we propose this approach as a general method for analysis.

Mesh:

Substances:

Year:  1997        PMID: 9679225     DOI: 10.1023/a:1025769431364

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  12 in total

Review 1.  Population pharmacokinetics/dynamics.

Authors:  L B Sheiner; T M Ludden
Journal:  Annu Rev Pharmacol Toxicol       Date:  1992       Impact factor: 13.820

2.  A nonparametric subject-specific population method for deconvolution: I. Description, internal validation, and real data examples.

Authors:  K E Fattinger; D Verotta
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

3.  A nonparametric subject-specific population method for deconvolution: II. External validation.

Authors:  K E Fattinger; D Verotta
Journal:  J Pharmacokinet Biopharm       Date:  1995-12

4.  Self-modelling with random shift and scale parameters and a free-knot spline shape function.

Authors:  M J Lindstrom
Journal:  Stat Med       Date:  1995-09-30       Impact factor: 2.373

5.  A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex.

Authors:  J M Gries; I F Troconiz; D Verotta; M Jacobson; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1997-01       Impact factor: 6.875

6.  Premarketing observational studies of population pharmacokinetics of new drugs.

Authors:  L B Sheiner; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

7.  Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography.

Authors:  L Yuh; S Beal; M Davidian; F Harrison; A Hester; K Kowalski; E Vonesh; R Wolfinger
Journal:  Biometrics       Date:  1994-06       Impact factor: 2.571

8.  A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation.

Authors:  K C Yeh; K C Kwan
Journal:  J Pharmacokinet Biopharm       Date:  1978-02

Review 9.  Population pharmacokinetics. Theory and clinical application.

Authors:  B Whiting; A W Kelman; J Grevel
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

10.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

Authors:  A C Collier; R W Coombs; D A Schoenfeld; R L Bassett; J Timpone; A Baruch; M Jones; K Facey; C Whitacre; V J McAuliffe; H M Friedman; T C Merigan; R C Reichman; C Hooper; L Corey
Journal:  N Engl J Med       Date:  1996-04-18       Impact factor: 91.245

View more
  4 in total

1.  Covariate detection in population pharmacokinetics using partially linear mixed effects models.

Authors:  Peter L Bonate
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

2.  Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats.

Authors:  D R H Huntjens; A Strougo; A Chain; A Metcalf; S Summerfield; D J M Spalding; M Danhof; O Della Pasqua
Journal:  Br J Pharmacol       Date:  2008-01-14       Impact factor: 8.739

3.  Nonparametric AUC estimation in population studies with incomplete sampling: a Bayesian approach.

Authors:  P Magni; R Bellazzi; G De Nicolao; I Poggesi; M Rocchetti
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

4.  Estimation of parameters for the elimination of an orally administered test substance with unknown absorption.

Authors:  Josef A Vogt; Christian Denzer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-02       Impact factor: 2.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.